Wednesday's Health Winners & Losers
St. Jude Medical's (STJ) shares gained 2.6% to $39.69 leading up to the company's quarterly earnings report slated for Thursday. A.G. Edwards analyst Jan Wald expects higher earnings in the third and fourth quarters, thanks to the company's new sales force.
Isis Pharmaceuticals (ISIS) gained 2.6% to $10.67 after the company announced a private placement of its $125 million offering convertible subordinated notes due 2027. The company is also issuing an additional $37.5 million in notes at the initial purchasers' option.
Lexicon Genetics (LEXG) shares gained 2.4% to $3.42 after the company said it's initiating a trial on a proposed treatment for irritable bowel syndrome and other gastrointestinal disorders. The drug, dubbed LX1031, will be tested for safety and efficacy in approximately 40 healthy volunteers.
Shares of Affymax (AFFY) gained 5.9% to $34.96 after analysts at RBC Capital Markets and Cowen & Co. initiated coverage of the stock with outperform ratings. According to Cowen analyst Phil Nadeau, data on the company's drug Hematide show the drug is effective and safe. Nadeau expects the drug to enter the market as a treatment for kidney disease patients in 2010 and to treat cancer-related anemia in late in 2011.Among other health stock winners Wednesday were Pfizer (PFE), 1.3% higher to $26.71; Emergent BioSolutions (EBS), gaining 8.6% to $17.38; NitroMed (NTMD), soaring 14.7% to $3.43; Novogen (NVGN), up 1.1% to $12.37; Cubist Pharmaceuticals (CBST), rising 2.6% to $18.06; and Introgen Therapeutics (INGN), whose shares were boosted 8.7% to $5.51. Among the losers were The Medicines Co. (MDCO), falling 3.6% to $29.33; Trinity Biotech (TRIB), off 1% to $9.19; Geron (GERN), 1.3% higher to $8.42 and Novo Nordisk (NVO), down 1.2% to $84.80.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV